GKOS
Glaukos Corporation
NYSE · Healthcare · Medical - Devices · US
$177.47
−1.60%Year over year
Reported trailing growth
- Revenue
- +41.5%
- EBITDA
- —
- EBIT
- +16.8%
- EPS
- -97.0%
- Free cash flow
- +54.7%
- Operating cash flow
- +95.4%
Forward estimates
Based on analyst estimates
- Revenue
- +23.4%
- EBITDA
- +138.9%
- EPS
- +104.7%
Three-year CAGR
- Revenue
- +21.5%
- EBITDA
- -52.7%
- EBIT
- +29.1%
- Net income
- -28.2%
- EPS
- -18.4%
- Free cash flow
- +20.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026